Liquid chromatographic method for the simultaneous analysis of antihypertensive and antilipidemic agents and interactions thereof

Patent metadata

Field	Value
Publication number	US-2020378942-A1
Application number	US-201916425668-A
Country	US
Kind code	A1
Filing date	May 29, 2019
Priority date	May 29, 2019
Publication date	Dec 3, 2020
Grant date	—

Abstract

The invention is directed to a precise, accurate and economical method for the simultaneous quantification of amounts of a dissolved sartan and dissolved statin in a mixture containing at least one sartan and at least one statin.

First claim

1 . A method for simultaneously quantifying amounts of a dissolved sartan and dissolved statin in a mixture containing at least one sartan and at least one statin, comprising:
contacting known amounts of least one sartan and at least one statin with one or more solvents to form a mixture, removing undissolved material from the mixture, applying the resulting mixture to a RP-HPLC column in a mobile phase comprising acetonitrile and water in a ratio of no greater than 70:30; quantifying amounts of the at least one sartan and at least one statin dissolved in the mixture by their UV absorption at 220-240 nm; and comparing the UV elution profile of the mixed sartan and statin to a control profile or to a profile of each individual not mixed drug.

2 . The method of claim 1 , wherein applying the mixture is performed using a mobile phase of acetonitrile to water of no more than 60:40 and wherein quantifying the at least one sartan and at least one statin in the mixture is by UV absorption at 225-235 nm.

3 . The method of claim 1 , wherein applying the mixture is performed using a mobile phase of acetonitrile to water of about 60:40 and wherein quantifying the at least one sartan and at least one statin in the mixture is by UV absorption at about 230 nm.

4 . The method of claim 1 , wherein the solvent has a pH of no more than 4.

5 . The method of claim 1 , wherein the solvent has a pH of more than 4 and no more than 7.

16 . The method of claim 1 , wherein the solvent has a pH of more than 7, but no more than 9.

7 . The method of claim 1 , wherein the at least one sartan and at least one statin comprises losartan and at least one of atorvastatin, pravastatin or simvastatin.

8 . The method of claim 1 , wherein the at least one sartan and at least one statin comprises losartan and at least two of atorvastatin, pravastatin or simvastatin.

9 . The method of claim 1 , the at least one sartan and at least one statin comprises losartan, atorvastatin, pravastatin and simvastatin.

10 . The method of claim 1 , wherein the at least one sartan and at least one statin comprises valsartan and at least one of atorvastatin, pravastatin or simvastatin.

11 . The method of claim 1 , wherein the at least one sartan and at least one statin comprises valsartan and at least two of atorvastatin, pravastatin or simvastatin.

12 . The method of claim 1 , wherein the at least one sartan and at least one statin comprises valsartan and atorvastatin, pravastatin and simvastatin.

13 . The method of claim 1 , wherein the at least one dissolved sartan and at least one dissolved statin contains at least one of losartan or valsartan and at least one of atorvastatin, pravastatin or simvastatin and wherein losartan has a concentration of 0.0075-0.03 mM, valsartan has a concentration of 0.0045-0.045 mM, atorvastatin has a concentration of 0.005-0.05 mM, pravastatin has a concentration of 0.005-0.05 mM and simvastatin has a concentration of 0.005-0.005 mM, when present in the mixture.

14 . The method of claim 1 , wherein said known amounts of the at least one sartan and at least one statin are contacted with at least two different solvents having different pHs, and wherein amounts of the at least one dissolved sartan and at least one dissolved statin are quantified in each solvent.

15 . The method of claim 14 , wherein the at least one sartan and at least one statin are contacted with solvents at pH 1, 4, 7.4 and 9 and wherein amounts of the at least one sartan and at least one statin are quantified in each solvent.

16 . The method of claim 14 , further comprising selecting or adjusting a drug regimen that comprises coadministration of the at least one sartan and at least one statin by selecting safe and effective dosages of the sartan and statin based on the amounts of sartan and dissolved in the solvents.

17 . The method of claim 14 , further comprising selecting a drug formulation providing safe and effective dosages of the at least one sartan and at least one statin based on the amounts of sartan and statin dissolved in the solvents.

18 . The method of claim 17 , wherein said drug formulation is formulated to release the at least one sartan in an acidic gastric compartment and the at least one statin in an alkaline luminal compartment, or vice versa.

19 . The method of claim 18 , wherein said drug formulation reduces an amount of the sartan and/or statin needed for efficacy compared to a drug formulation where both sartan and statin are released into the same compartment.

20 . The method of claim 17 , wherein said drug formulation is formulated to release the at least one sartan and the at least one statin into the same gastric or luminal compartment.

Assignees

• Univ Imam Abdulrahman Bin Faisal

Inventors

• Qureshi Faiza
• Nawaz Muhammad

Classifications

• G01N33/15 Primary

  Medicinal preparations {; Physical properties thereof, e.g. dissolubility} · CPC title

• C07D309/30 Primary

  Oxygen atoms, e.g. delta-lactones · CPC title

• C07D257/04

  Five-membered rings · CPC title

• B01D15/325

  Reversed phase · CPC title

• B01D15/22

  relating to the construction of the column · CPC title